These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38982928)

  • 1. Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer.
    Wenzel M; Hoeh B; Koll F; Humke C; Fassl A; Reis H; Wild P; Steuber T; Graefen M; Tilki D; Traumann M; Banek S; Chun FKH; Mandel P
    BJU Int; 2025 Jan; 135(1):117-124. PubMed ID: 38982928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With
    Wenzel M; Koll F; Hoeh B; Humke C; Reis H; Wild P; Steuber T; Graefen M; Tilki D; Sabet A; Gröner D; Chun FKH; Mandel P
    JCO Precis Oncol; 2024 Dec; 8():e2400645. PubMed ID: 39642328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and outcomes of germline pathogenic variants of homologous recombination repair genes in ovarian cancer.
    Miwa M; Kitagawa M; Asami Y; Kobayashi-Kato M; Watanabe T; Ogasawara A; Hiranuma K; Kato H; Saito M; Miyagi Y; Kato T; Yoshida H; Momozawa Y; Kohno T; Shiraishi K; Hasegawa K
    Cancer Sci; 2024 Dec; 115(12):3952-3962. PubMed ID: 39385713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [
    Muniz M; Sartor O; Orme JJ; Koch RM; Rosenow HR; Mahmoud AM; Andrews JR; Kase AM; Riaz IB; Belge Bilgin G; Thorpe MP; Kendi AT; Johnson GB; Ravi P; Kwon ED; Childs DS
    J Nucl Med; 2024 Dec; 65(12):1932-1938. PubMed ID: 39477495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in the expression of homologous recombination repair (HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation status.
    Laczmanska I; Matkowski R; Supplitt S; Karpinski P; Abrahamowska M; Laczmanski L; Maciejczyk A; Czykalko E; Iwaneczko E; Kasprzak P; Szynglarewicz B; Sasiadek M
    Breast Cancer Res Treat; 2024 Dec; 208(3):501-510. PubMed ID: 39080120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer.
    Fiegl H; Schnaiter S; Reimer DU; Leitner K; Nardelli P; Tsibulak I; Wieser V; Wimmer K; Schamschula E; Marth C; Zeimet AG
    Clin Epigenetics; 2024 Nov; 16(1):171. PubMed ID: 39605059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Ai J; Jian L; Wen X; Huo X; Yang X; Jiang J; Zhang T
    Clin Transl Oncol; 2024 Oct; 26(10):2559-2571. PubMed ID: 38750344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors.
    Chou J; Robinson TM; Egusa EA; Lodha R; Zhang M; Badura M; Mikayelyan M; Delavan HM; Swinderman J; Wilson C; Zhu J; Das R; Nguyen M; Loehr A; Golsorkhi T; Simmons A; Abida W; Chinnaiyan AM; Arkin MR; Small EJ; Quigley DA; Yang L; Kim M; Ashworth A; Feng FY
    Clin Cancer Res; 2024 Dec; 30(23):5445-5458. PubMed ID: 39321214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer.
    Zacchi F; Abida W; Antonarakis ES; Bryce AH; Castro E; Cheng HH; Shandhu S; Mateo J
    Eur Urol Oncol; 2024 Dec; ():. PubMed ID: 39638687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Combination AKT and Androgen Receptor Signaling Inhibition in Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis.
    Nahar TAK; Bantounou MA; Savin I; Chohan N; Kumar NS; Ghose A; McEwan IJ
    Clin Genitourin Cancer; 2024 Dec; 22(6):102244. PubMed ID: 39549658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial.
    van Wilpe S; Kloots ISH; Slootbeek PHJ; den Brok M; Westdorp H; Franken MD; Coskunturk M; Osinga T; Bloemendal H; Adema G; Smeenk RJ; Nagarajah J; van Ipenburg J; Kroeze LI; Ligtenberg MJL; Schalken J; Gerritsen WR; Mehra N
    Ann Oncol; 2024 Dec; 35(12):1126-1137. PubMed ID: 39293514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Sachdeva A; Jones C; Hoyle A; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Gilson C; Rush H; Abdel-Aty H; Amos CL; Murphy C; Chowdhury S; Malik Z; Russell JM; Parkar N; Pugh C; Diaz-Montana C; Pezaro C; Grant W; Saxby H; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzouebi M; Parikh O; Robinson A; Montazeri AH; Wylie J; Zarkar A; Cathomas R; Brown MD; Jain Y; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet Oncol; 2023 May; 24(5):443-456. PubMed ID: 37142371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
    Fallah J; Xu J; Weinstock C; Gao X; Heiss BL; Maguire WF; Chang E; Agrawal S; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman DL
    J Clin Oncol; 2024 May; 42(14):1687-1698. PubMed ID: 38484203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE Trial.
    Rans K; Joniau S; Berghen C; Goffin K; Dumez H; Haustermans K; De Meerleer G
    Eur Urol Oncol; 2024 Dec; 7(6):1441-1450. PubMed ID: 38664137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database Study.
    Shao C; Ren Y; Zhou H; Lee LC; Chen C; Dettman EJ; Cristescu R; Gozman A; Jin F; Zhou W
    Adv Ther; 2024 Feb; 41(2):759-776. PubMed ID: 38169059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
    Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
    Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine.
    Panagopoulou M; Panou T; Gkountakos A; Tarapatzi G; Karaglani M; Tsamardinos I; Chatzaki E
    Clin Epigenetics; 2024 Dec; 16(1):178. PubMed ID: 39643918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing BRCA 1-2 Mutations in Metastatic Prostate Cancer: Results of a Survey of the Italian Association of Medical Oncology.
    Saporita I; Calabrese M; Poletto S; Turco F; Di Stefano RF; Caffo O; Russo A; De Giorgi U; Tucci M; Di Maio M; Cinieri S; Buttigliero C
    Clin Genitourin Cancer; 2024 Nov; 23(1):102255. PubMed ID: 39615118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review.
    Baboudjian M; Peyrottes A; Dariane C; Fromont G; Denis JA; Fiard G; Kassab D; Ladoire S; Lehmann-Che J; Ploussard G; Rouprêt M; Barthélémy P; Roubaud G; Lamy PJ
    Eur Urol Oncol; 2024 Dec; 7(6):1228-1245. PubMed ID: 38824003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.